CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements
Questions Remain Around Long-Term Use
Neurologists shared their health care facilities’ protocols as they begin treating Alzheimer’s patients with the first anti-amyloid treatment to win both US FDA approval and Medicare coverage – Eisai/Biogen’s Leqembi.
